Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Effect of ibandronate on bone loss and renal function after kidney transplantation.

Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC.

J Am Soc Nephrol. 2001 Jul;12(7):1530-7.

2.

Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials.

Palmer SC, Strippoli GF, McGregor DO.

Am J Kidney Dis. 2005 Apr;45(4):638-49. Review.

PMID:
15806466
3.

Treatment for osteoporosis in people with ß-thalassaemia.

Bhardwaj A, Swe KM, Sinha NK, Osunkwo I.

Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2. Review.

PMID:
26964506
4.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
5.

Beyond daily dosing: clinical experience.

Cooper C.

Bone. 2006 Apr;38(4 Suppl 1):S13-7. Epub 2006 Mar 7. Review.

PMID:
16520105
6.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
8.
9.

Interventions for preventing bone disease in kidney transplant recipients.

Palmer SC, McGregor DO, Strippoli GF.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005015. Review.

PMID:
17636784
10.
11.

[Bone metabolism alterations after kidney transplantation].

Torres A, García S, Barrios Y, Hernández D, Lorenzo V.

Nefrologia. 2003;23 Suppl 2:122-6. Review. Spanish.

12.

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

Bauss F, Russell RG.

Osteoporos Int. 2004 Jun;15(6):423-33. Epub 2004 Mar 26. Review.

PMID:
15205712

Supplemental Content

Support Center